Allergan conducting Phase III program for Posurdex in Korea

Published: 2006-11-01 06:57:00

Updated: 2006-11-01 06:57:00

Allergan, the U.S.-based global health care company, is currently conducting two Phase III clinical programs in 100 hospitals worldwide with Posurdex, the first biodegradable ocular implant, focusing on macular edema associated with diabetes and other conditions, according to Allergan Korea.

In Korea, several leading hospitals including Seoul Asan Medical Center, Seoul National University Ho...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.